CytomX Therapeutics (CTMX) Short-term Investments (2015 - 2026)

CytomX Therapeutics has reported Short-term Investments for 12 years, with the latest figure at $317.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 884.69% year-over-year to $317.9 million; the trailing twelve-month figure through Mar 2026 stood at $317.9 million (up 884.69% YoY), and the FY2025 full-year result was $124.4 million, up 98.79% from the prior year.
• Short-term Investments for Q1 2026 stood at $317.9 million, up from $124.4 million in the prior quarter.
• The five-year high for Short-term Investments was $317.9 million in Q1 2026, with the low at $32.3 million in Q1 2025.
• Historically, Short-term Investments has averaged $120.9 million across 5 years, with a median of $109.2 million in 2025.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 1984980.0% — and 2025, when it slumped 71.71%.
• CytomX Therapeutics' Short-term Investments stood at $99.3 million in 2022, then jumped by 58.52% to $157.3 million in 2023, then plunged by 60.23% to $62.6 million in 2024, then soared by 98.79% to $124.4 million in 2025, then jumped by 155.56% to $317.9 million in 2026.
• The last three Short-term Investments figures came in at $317.9 million (Q1 2026), $124.4 million (Q4 2025), and $109.4 million (Q3 2025), per Business Quant data.